UCB Consensus
Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.
In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of more than 25 different brokers.
If you wish to be informed whenever we have updated consensus, simply send an e-mail to This e-mail address is being protected from spam bots, you need JavaScript enabled to view it quoting "consensus email alert" as subject.
| UCB Consensus Product Sales Estimates | ||||||
| In € million | 2012e | 2013e | 2014e | 2015e | 2016e | 2017e |
| Cimzia | 475 | 633 | 777 | 904 | 990 | 1,039 |
| Vimpat | 329 | 458 | 596 | 740 | 884 | 925 |
| Neupro | 135 | 184 | 236 | 281 | 282 | 284 |
| UCB Consensus Earnings Estimates | |||
| In € million | 2012e | 2013e | 2014e |
| Revenues | 3,131 | 3,265 | 3,495 |
| Recurring EBIT | 401 | 458 | 550 |
| Recurring EBITDA | 653 | 710 | 797 |
| Net Profit | 201 | 245 |
323 |
| Core EPS (€) | 1.68 | 1.93 | 2.37 |
Last updated: March 27, 2012
Disclaimer:
This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.